Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHIMERA: Pembrolizumab + Chemotherapy in Resectable Pleural Mesothelioma
NCT06155279Phase 2Active, not recruiting
- Sponsor
- Istituto Oncologico Veneto
- Start
- Nov 2024
- Primary completion
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in pleural mesothelioma, sponsored by Istituto Oncologico Veneto. Primary endpoint: Pathological Complete Response Rate. Started Nov 2024; status: active, not recruiting.
02
Drugs
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on NCT06155279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06155279.